Navigation Links
Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Date:5/21/2008

ommercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the ongoing clinical testing of voreloxin, potential safety and efficacy and commercial potential of voreloxin, planned additional clinical testing and development efforts, the timing of enrollment of patients in the company's clinical trials, the adoption of voreloxin as a nonproprietary name and the announcement of clinical results. Words such as "expect," "will," "opportunity," "plans," "could," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk tha
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
2. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
3. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
4. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015  QT Vascular Ltd., ... a global company engaged in the design, assembly and ... treatment of vascular disease, has entered into an agreement ... to US$13.14 million convertible bond investment. This funding will ... its growth to the next milestone. ...
(Date:7/27/2015)... July 27, 2015 As per the ... - Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... 7.96 billion in 2014, growing at a CAGR of 13.2% ... in 2021. The global bionics market is growing ... which is leading to paralysis or amputation of body parts. ...
(Date:7/27/2015)... SALT LAKE CITY , July 27, 2015 Dynatronics ... Mark approval for its Solaris therapeutic modality products. This approval allows ... and many other countries around the world. "Receiving ... our international sales efforts," stated Kelvyn H. Cullimore Jr. , ... have expanded our distribution network into China , ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... Medical Imaging of Fredericksburg is one of six ...  Best of 2011 Radiology Facilities issue, a national ... In an article titled "Small Town Sensibility, ... of Fredericksburg, a partnership between Mary Washington Healthcare ...
... Hologic, Inc. (Hologic or the Company) (Nasdaq: ... premium diagnostic products, medical imaging systems and surgical products ... focus on two new, ready-to-market automated options for cervical ... Clinical Workshop (IPV) September 17th through 22nd in ...
Cached Medicine Technology:Medical Imaging of Fredericksburg Highlighted in Imaging Economics' Best of 2011 Radiology Facilities Issue 2Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 2Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 3Hologic Launches Automated Cervical Cancer Screening Solutions at IPV Meeting in Berlin 4
(Date:7/28/2015)... ... July 28, 2015 , ... One of the ... World Magazine, is plantar fasciitis . Zensah, the Miami-based compression brand, offers ... a professional athletic trainer, the Zensah Ankle Support’s primary benefits include helping support ...
(Date:7/28/2015)... ... 2015 , ... American Sentinel University has been named an ... Geisinger Health System (GHS), one of the nation’s largest integrated health services organizations. ... access to American Sentinel’s affordable, flexible and CCNE-accredited RN to BSN nursing degree ...
(Date:7/28/2015)... ... 28, 2015 , ... Carol McFarland, PT, PhD, OCS focuses ... of specific rehabilitation exercises and treatment protocols in the PTA OT PT ... extensive interview conducted by Carol with a board certified neurosurgeon. Specific case studies ...
(Date:7/28/2015)... ... July 28, 2015 , ... Want to improve your fitness level ... your easy chair? Luckily, there are plenty of back-friendly cardio exercises that are safe ... surgeon at Atlantic Spine Center . , It’s simply untrue that those ...
(Date:7/27/2015)... ... 2015 , ... Career Step, an online provider of career-focused education and corporate ... nationally endorsed on The Dave Ramsey Show. Dave’s endorsement can be heard on over ... , “It is a privilege to be highlighted on The Dave Ramsey Show,” said ...
Breaking Medicine News(10 mins):Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 3Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 5Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 6Health News:Safe Cardio for Back Pain Sufferers 2Health News:Safe Cardio for Back Pain Sufferers 3Health News:Career Step Nationally Endorsed on The Dave Ramsey Show 2Health News:Career Step Nationally Endorsed on The Dave Ramsey Show 3
... can learn much from each other in regard ... wrong-site surgeries, HARRISBURG, Pa., Jan. 10 ... decreased during 2007, some,facilities continue to report wrong-site ... protocols implemented by other Pennsylvania,facilities that have been ...
... Prepares to Release Alarming New HIV Rates; Governor ... 10 AIDS Healthcare,Foundation (AHF) today urged California ... of proposed budget cuts in AIDS services,that will ... for,Californians living with HIV/AIDS as he seeks to ...
... for "The Grove Circle," Honoring Planned Gift Donors,Reflects Shared ... - Andrew S. Grove,co-founder of technology giant Intel and ... Research, announced his intent to bequeath a,portion of his ... Fox Foundation.,Mr. Grove,s gift will establish The Grove Circle, ...
... can alter timetable , , THURSDAY, Jan. 10 (HealthDay News) -- ... a half years following their diagnosis, new British research shows. ... life expectancy, according to the report in the Jan. 11 ... Common socioeconomic influences, such as marital status, social class and ...
... January 9, 2008 In a study published ... from the University of Aberdeen report that the ... and praised as "the first and,only representative of ... fact similar,to other existing compounds, and is beneficial ...
... Animal study shows preconditioning cardiac cells helps organ better tolerate ... -- Just as daily runs can prepare you to survive ... spells could condition cardiac cells to better withstand the damage ... University of Cincinnati suggests. , Ultimately, if validated in humans, ...
Cached Medicine News:Health News:Patient Safety Authority Visits Facilities for Information on Wrong-Site Surgery 2Health News:Patient Safety Authority Visits Facilities for Information on Wrong-Site Surgery 3Health News:Patient Safety Authority Visits Facilities for Information on Wrong-Site Surgery 4Health News:AHF to Schwarzenegger: 'AIDS Cuts Are Deadly' 2Health News:AHF to Schwarzenegger: 'AIDS Cuts Are Deadly' 3Health News:Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation 2Health News:Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation 3Health News:Dementia Diagnosis Typically Means Death Within Five Years 2Health News:Memantine and Alzheimer's disease 2Health News:Memantine and Alzheimer's disease 3Health News:Priming Heart Before an Attack Could Limit Damage 2Health News:Priming Heart Before an Attack Could Limit Damage 3
... This comprehensive guide provides safe, ... administration information in a quickly ... 2006 edition includes the latest ... with key nursing implications are ...
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
... Nurse's Pocket Drug Guide 2005 includes over ... data relating to their selection and administration. ... each drug includes key data featuring common ... nursing implications and patient education information. A ...
... is a dynamic new mobile tool ... to check on the compatibility of ... drugs, clear compatibility and stability results ... take clinical action based on this ...
Medicine Products: